Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Cancer antigen services mainly include detecting, characterizing, and analyzing cancer-related antigens, serving as the foundation for subsequent cancer vaccine development. This involves knowledge in biomedical fields such as cancer immunology and molecular biology and the support of specialized laboratory biotechnology and biological instruments. Alfa Cytology offers comprehensive cancer antigen services based on our technical expertise and extensive experience.
Fig. 1 The significance of cancer antigen discovery in cancer immunotherapy. (Ryuhjin, A., et al., 2023)
Research has shown that new epitope antigens derived from autologous cell mutations can be generated in tumors and may appear on the surface of tumor cells. Then these new epitopes can be recognized by tumor infiltrating lymphocytes, enabling them to kill the tumor. Most cancer vaccines use the immunological reactions mentioned above to treat cancer.
Overall, cancer antigens play a crucial cornerstone role in the development of cancer vaccines. With our proven technology systems and extensive industry experience, Alfa Cytology offers a full range of cancer antigen services. Our cancer antigen services mainly include the following.
Tumor Antigens in Silico Prediction Services
The three-dimensional structure and gene sequence of antigens determine the performance and location of antigen epitopes. Therefore, tumor antigen in silico prediction technology is one of the important means of predicting and identifying antigen epitopes.
Cancer Antigenic Epitope Study Services
Cancer vaccines not only require cancer antigens but also require modification or selection of appropriate peptide fragments based on the body's conditions for vaccine development. It is necessary to conduct in-depth research on cancer antigens before development.
Tumor-associated Antigen Identification Services
Tumor-associated antigens are not unique to tumor cells. Normal cells can synthesize them in trace amounts, but they are highly expressed during tumor cell proliferation. The successful identification of tumor-associated antigens is beneficial for identifying biomarkers and immune recognition targets, as well as long-term disease detection and vaccine development.
Tumor-specific Antigen Identification Services
Tumor-specific antigen refers to a new antigen that is only expressed on the surface of certain tumor cells and does not exist on normal cells, mainly inducing T cell immune response. Genetic testing of identification methods can identify genes that undergo mutations compared to normal tissue by analyzing the gene sequence of tumor tissue.
The above services all involve complex experimental processes, and Alfa Cytology has a professional experimental platform and a group of experienced laboratory personnel to escort each project.
We have extensive experience in the field of cancer vaccine development.
We can provide customized solutions based on specific customer needs and project objectives.
We have advanced laboratory facilities and technology platforms.
We are committed to providing high-quality research results and reliable data support.
Alfa Cytology has extensive experience in the field of cancer vaccine development, with a focus on a series of services related to cancer antigens in the early stages of development. If you are interested in our services, please contact us to get more information.
Reference